27132-53-2

Usage

Uses

Used in Pharmaceutical Industry:
10-methylpyrimido[4,5-b]quinoline-2,4(3H,10H)-dione is used as a lead compound for the development of anti-cancer drugs due to its ability to inhibit histone deacetylases, which can modulate gene expression and exhibit anti-tumor activity.
Used in Epigenetic Regulation Research:
In the field of epigenetics, 10-methylpyrimido[4,5-b]quinoline-2,4(3H,10H)-dione serves as a valuable tool for studying the role of histone acetylation in gene regulation and the potential therapeutic implications of modulating these processes.
Used in Drug Discovery for Epigenetic Therapies:
10-methylpyrimido[4,5-b]quinoline-2,4(3H,10H)-dione is utilized as a starting point for the design and synthesis of novel HDAC inhibitors, aiming to develop more effective and targeted treatments for cancer and other diseases influenced by epigenetic mechanisms.
Used in Cancer Treatment:
Trapoxin A is considered for use as a therapeutic agent in oncology, specifically for the treatment of various types of cancer, by leveraging its HDAC inhibitory properties to disrupt the epigenetic mechanisms that contribute to tumor growth and progression.

InChI:InChI=1/C12H9N3O2/c1-15-9-5-3-2-4-7(9)6-8-10(15)13-12(17)14-11(8)16/h2-6H,1H3,(H,14,16,17)

Upstream product

• 1033542-88-9 2-amino-4-chloro-6-[methyl(phenyl)amino]pyrimidine-5-carbaldehyde 
• 34284-87-2 6-(methylamino)pyrimidine-2,4(1H,3H)-dione 
• 446-52-6 2-Fluorobenzaldehyde 
• 948578-68-5 C₁₃H₁₁N₃SO 

Relevant academic research and scientific papers

5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2

Based on previous reports of certain 5-deazaflavin derivatives being capable of activating the tumour suppressor p53 in cancer cells through inhibition of the p53-specific ubiquitin E3 ligase HDM2, we have conducted an structure-activity relationship (SAR) analysis through systematic modification of the 5-deazaflavin template. This analysis shows that HDM2-inhibitory activity depends on a combination of factors. The most active compounds (e.g., 15) contain a trifluoromethyl or chloro substituent at the deazaflavin C9 position and this activity depends to a large extent on the presence of at least one additional halogen or methyl substituent of the phenyl group at N10. Our SAR results, in combination with the HDM2 RING domain receptor recognition model we present, form the basis for the design of drug-like and potent activators of p53 for potential cancer therapy.

Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II

The recently discovered enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2) has been implicated in the topoisomerase-mediated repair of DNA damage. In the clinical setting, it has been hypothesized that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide. Therefore, selective pharmacological inhibition of TDP2 is proposed as a novel approach to overcome intrinsic or acquired resistance to topo II-targeted drug therapy. Following a high-throughput screening (HTS) campaign, toxoflavins and deazaflavins were identified as the first reported sub-micromolar and selective inhibitors of this enzyme. Toxoflavin derivatives appeared to exhibit a clear structure-activity relationship (SAR) for TDP2 enzymatic inhibition. However, we observed a key redox liability of this series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, precluded further exploration. The deazaflavins were developed from a singleton HTS hit. This series showed distinct SAR and did not display redox activity; however low cell permeability proved to be a challenge.

A straightforward synthesis of pyrimido[4,5-b]quinoline derivatives assisted by microwave irradiation

Several pyrimido[4,5-b]quinolines, flavin analogues, have been prepared by assisted microwave intramolecular cyclization of N4-substituted-2,4-diamino-6-chloropyrimidine-5-carbaldehydes. The reaction takes place with hydrolysis of amino-group and chlorine. Particularly valuable features of this method included the broader substrate scope and operational simplicity as well as increased safety for small-scale high-speed synthesis.

Antitumor studies. Part 3: Design, synthesis, antitumor activity, and molecular docking study of novel 2-methylthio-, 2-amino-, and 2-(N-substituted amino)-10-alkyl-2-deoxo-5-deazaflavins

Various novel 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins have been synthesized by reaction of 6-(N-alkylanilino)-2-methylthiopyrimidin-4(3H)-ones with Vilsmeier reagent. The similar 2-(N-substituted amino) derivatives were prepared by nucleophilic replacement reaction of the 2-methylthio moiety by appropriate amines. The 2-oxo derivatives (i.e., 5-deazaflavins) were obtained by acidic hydrolysis of the 2-methylthio derivatives. The antitumor activities against CCRF-HSB-2 and KB cells and the antiviral activities against HSV-1 and HSV-2 have been investigated in vitro, and many compounds showed promising antitumor activities. Furthermore, AutoDock molecular docking into PTK has been done for lead optimization of these compounds as potential PTK inhibitors. Whereas, the designed 2-deoxo-5-deazaflavins connected with amino acids at the 2-position exhibited the good binding affinities into PTK with more hydrogen bonds.